201 related articles for article (PubMed ID: 16643621)
21. HtrA3 is regulated by 15-deoxy-Delta12,14-prostaglandin J2 independently of PPARgamma in clear cell renal cell carcinomas.
Théoleyre S; Mottier S; Masson D; Denis MG
Biochem Biophys Res Commun; 2010 Apr; 394(3):453-8. PubMed ID: 19951697
[TBL] [Abstract][Full Text] [Related]
22. Low expression of ORF4, a dominant negative variant of peroxisome proliferator-activated receptor gamma, in colorectal adenocarcinoma.
Bouancheau D; Jarry A; Mottier S; Toquet C; Masson D; Mosnier JF; Laboisse CL; Denis MG
Oncol Rep; 2007 Aug; 18(2):489-95. PubMed ID: 17611675
[TBL] [Abstract][Full Text] [Related]
23. PPARγ is functionally expressed in clear cell renal cell carcinoma.
Collet N; Théoleyre S; Rageul J; Mottier S; Jouan F; Rioux-Leclercq N; Fergelot P; Patard JJ; Masson D; Denis MG
Int J Oncol; 2011 Mar; 38(3):851-7. PubMed ID: 21206970
[TBL] [Abstract][Full Text] [Related]
24. The expression of ketohexokinase is diminished in human clear cell type of renal cell carcinoma.
Hwa JS; Kim HJ; Goo BM; Park HJ; Kim CW; Chung KH; Park HC; Chang SH; Kim YW; Kim DR; Cho GJ; Choi WS; Kang KR
Proteomics; 2006 Feb; 6(3):1077-84. PubMed ID: 16372272
[TBL] [Abstract][Full Text] [Related]
25. Up-regulation of functional chemokine receptor CCR3 in human renal cell carcinoma.
Jöhrer K; Zelle-Rieser C; Perathoner A; Moser P; Hager M; Ramoner R; Gander H; Höltl L; Bartsch G; Greil R; Thurnher M
Clin Cancer Res; 2005 Apr; 11(7):2459-65. PubMed ID: 15814620
[TBL] [Abstract][Full Text] [Related]
26. Expression of peroxisome proliferator-activated receptor gamma, E-cadherin and matrix metalloproteinases-2 in gastric carcinoma and lymph node metastases.
He Q; Chen J; Lin HL; Hu PJ; Chen MH
Chin Med J (Engl); 2007 Sep; 120(17):1498-504. PubMed ID: 17908458
[TBL] [Abstract][Full Text] [Related]
27. Expression and regulation of non-classical HLA-G in renal cell carcinoma.
Dunker K; Schlaf G; Bukur J; Altermann WW; Handke D; Seliger B
Tissue Antigens; 2008 Aug; 72(2):137-48. PubMed ID: 18721274
[TBL] [Abstract][Full Text] [Related]
28. Expression of indoleamine 2,3-dioxygenase in tumor endothelial cells correlates with long-term survival of patients with renal cell carcinoma.
Riesenberg R; Weiler C; Spring O; Eder M; Buchner A; Popp T; Castro M; Kammerer R; Takikawa O; Hatz RA; Stief CG; Hofstetter A; Zimmermann W
Clin Cancer Res; 2007 Dec; 13(23):6993-7002. PubMed ID: 18056175
[TBL] [Abstract][Full Text] [Related]
29. Different vascular endothelial growth factor (VEGF), VEGF-receptor 1 and -2 mRNA expression profiles between clear cell and papillary renal cell carcinoma.
Ljungberg BJ; Jacobsen J; Rudolfsson SH; Lindh G; Grankvist K; Rasmuson T
BJU Int; 2006 Sep; 98(3):661-7. PubMed ID: 16925769
[TBL] [Abstract][Full Text] [Related]
30. Expression of Ets-1 in human clear cell renal cell carcinomas: implications for angiogenesis.
Mikami S; Oya M; Mizuno R; Murai M; Mukai M; Okada Y
Cancer Sci; 2006 Sep; 97(9):875-82. PubMed ID: 16856880
[TBL] [Abstract][Full Text] [Related]
31. Tissue expression and plasma levels of adrenomedullin in renal cancer patients.
Michelsen J; Thiesson H; Walter S; Ottosen PD; Skøtt O; Jensen BL
Clin Sci (Lond); 2006 Jul; 111(1):61-70. PubMed ID: 16515534
[TBL] [Abstract][Full Text] [Related]
32. Expression of genes involved in chemoresistance, proliferation and apoptosis in clinical samples of renal cell carcinoma and correlation with clinical outcome.
Oudard S; Levalois C; Andrieu JM; Bougaran J; Validire P; Thiounn N; Poupon MF; Fourme E; Chevillard S
Anticancer Res; 2002; 22(1A):121-8. PubMed ID: 12017273
[TBL] [Abstract][Full Text] [Related]
33. Differential expression of activator protein-2 isoforms in renal cell carcinoma.
Oya M; Mikami S; Mizuno R; Miyajima A; Horiguchi Y; Nakashima J; Marumo K; Mukai M; Murai M
Urology; 2004 Jul; 64(1):162-7. PubMed ID: 15245963
[TBL] [Abstract][Full Text] [Related]
34. Expression of death-associated protein kinase during tumour progression of human renal cell carcinomas: hypermethylation-independent mechanisms of inactivation.
Wethkamp N; Ramp U; Geddert H; Schulz WA; Florl AR; Suschek CV; Hassan M; Gabbert HE; Mahotka C
Eur J Cancer; 2006 Jan; 42(2):264-74. PubMed ID: 16386893
[TBL] [Abstract][Full Text] [Related]
35. Peroxisome proliferator-activated receptor gamma is highly expressed in pancreatic cancer and is associated with shorter overall survival times.
Kristiansen G; Jacob J; Buckendahl AC; Grützmann R; Alldinger I; Sipos B; Klöppel G; Bahra M; Langrehr JM; Neuhaus P; Dietel M; Pilarsky C
Clin Cancer Res; 2006 Nov; 12(21):6444-51. PubMed ID: 17085658
[TBL] [Abstract][Full Text] [Related]
36. Differential protein profiling in renal-cell carcinoma.
Shi T; Dong F; Liou LS; Duan ZH; Novick AC; DiDonato JA
Mol Carcinog; 2004 May; 40(1):47-61. PubMed ID: 15108329
[TBL] [Abstract][Full Text] [Related]
37. A peroxisome proliferator-activated receptor gamma antagonist induces vimentin cleavage and inhibits invasion in high-grade hepatocellular carcinoma.
Kim KR; Choi HN; Lee HJ; Baek HA; Park HS; Jang KY; Chung MJ; Moon WS
Oncol Rep; 2007 Oct; 18(4):825-32. PubMed ID: 17786342
[TBL] [Abstract][Full Text] [Related]
38. Effects of peroxisome proliferator-activated receptor activation on gonadotropin transcription and cell mitosis induced by bone morphogenetic proteins in mouse gonadotrope LbetaT2 cells.
Takeda M; Otsuka F; Otani H; Inagaki K; Miyoshi T; Suzuki J; Mimura Y; Ogura T; Makino H
J Endocrinol; 2007 Jul; 194(1):87-99. PubMed ID: 17592024
[TBL] [Abstract][Full Text] [Related]
39. Expression of beta-catenin in renal cell carcinoma.
Zang T; Zhuang L; Zhang Z; Xin D; Guo Y
Chin Med J (Engl); 2001 Feb; 114(2):152-4. PubMed ID: 11780196
[TBL] [Abstract][Full Text] [Related]
40. Analysis of the expression of HLA class I, proinflammatory cytokines and chemokines in primary tumors from patients with localized and metastatic renal cell carcinoma.
Romero JM; Aptsiauri N; Vazquez F; Cozar JM; Canton J; Cabrera T; Tallada M; Garrido F; Ruiz-Cabello F
Tissue Antigens; 2006 Oct; 68(4):303-10. PubMed ID: 17026465
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
